Related Experiment Video

Updated: Dec 12, 2025

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.0K

Outcomes in children with hemophilia A with inhibitors: Results from a noninterventional study

Johannes Oldenburg1, Midori Shima2, Rebecca Kruse-Jarres3

  • 1Institute of Experimental Hematology and Transfusion Medicine, Universitätsklinikum Bonn, Bonn, Germany.

Pediatric Blood & Cancer
|August 11, 2020
PubMed

Insights

Pediatric persons with hemophilia A (PwHA) and factor VIII (FVIII) inhibitors experience high bleeding rates on standard treatment. This study highlights the urgent need for improved therapies to reduce bleeding and enhance quality of life.

Area of Science:

  • Pediatric Hematology
  • Hemophilia A Treatment
  • Factor VIII Inhibitors

Background:

  • Limited data exists on managing pediatric patients with hemophilia A (PwHA) who develop factor VIII (FVIII) inhibitors.
  • This study addresses the need for better understanding of current treatment outcomes in this population.

Purpose of the Study:

  • To evaluate annualized bleeding rates (ABRs), safety, and health-related quality of life (HRQoL) in pediatric PwHA with FVIII inhibitors.
  • To assess outcomes in children receiving standard episodic or prophylactic treatments.

Main Methods:

  • A prospective, non-interventional study (NCT02476942) enrolled 24 pediatric PwHA (<12 years) with current FVIII inhibitors.
  • Participants received their usual care, with outcomes including ABRs, safety events, and HRQoL measured over a median of 23.4 weeks.

Main Results:

  • High ABRs were observed in both episodic (32.7) and prophylactic (33.1) groups.
  • Activated prothrombin complex concentrate (aPCC) and recombinant activated FVII (rFVIIa) were used for bleed management, with 50% adherence to prophylactic aPCC.
  • Serious adverse events included hemarthrosis and mouth hemorrhage; HRQoL remained stable but indicated functional impairment.

Conclusions:

  • Current standard treatments result in high ABRs for pediatric PwHA with inhibitors.
  • There is a critical need for more effective treatments that reduce bleeding frequency, improve adherence to prophylaxis, and enhance patient outcomes.
Abstract

Keywords:
FVIIIblood coagulation factor inhibitorsemicizumabhealth-related quality of lifehemophilia Anoninterventional study

More Related Videos

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection09:35

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection

Published on: February 2, 2018

14.9K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

11.0K

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
180
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
309
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K